文献速递胃肠动力与功能性疾病消化内镜

胃经口内镜下肌切开术治疗置入胃神经刺激器装置的难治性胃轻瘫患者:多中心回顾性病例对照研究

Gastric peroral endoscopic myotomy for management of refractory gastroparesis in patients with gastric neurostimulator devices: a multicenter retrospective case control study.
PubMed 文献 · Gastrointest Endosc · 2023-04-28

多中心回顾性匹配病例对照研究纳入2018年10月至2021年8月接受胃经口内镜下肌切开术(G-POEM)的123例难治性胃轻瘫患者,比较胃神经刺激(GNS)装置植入后临床失败行G-POEM补救治疗者(41例)与未植入GNS者(82例)。两组临床成功率分别为66%与65%(P=.311)。病例组胃轻瘫主要症状指数评分从2.8±1.8降至1.5±1.9(P=.024),恶心/呕吐与腹胀子量表改善幅度病例组高于对照组。

要点

  • GNS植入后难治性症状患者行G-POEM补救治疗,临床成功率为66%,与未植入GNS者的65%无显著差异。
  • 病例组G-POEM后胃轻瘫主要症状指数评分从2.8±1.8降至1.5±1.9(P=.024)。
  • 恶心/呕吐与腹胀子量表改善幅度病例组高于对照组,作者认为G-POEM可作为补救治疗提供进一步症状缓解。

核心结论

  • 在胃神经刺激(GNS)植入后仍存在难治性症状的患者中,G-POEM可作为合理的补救治疗以提供进一步症状缓解,并有证据提示G-POEM与GNS可能存在叠加效应。

研究设计与样本

  • 多中心、回顾性、匹配病例对照研究,纳入2018年10月至2021年8月连续患者,病例组为植入GNS装置后因临床失败行G-POEM补救治疗者,对照组为未植入GNS而行G-POEM治疗难治性胃轻瘫者。
  • 共123例患者接受G-POEM治疗,平均年龄45.7±14.7岁,女性88例(72%);病例组41例,对照组82例。

主要发现

  • 中位临床随访总时间11.8(四分位距2.4-6.3)个月,病例组临床成功率66%,对照组65%(P=.311)。
  • 病例组胃轻瘫主要症状指数平均评分从2.8±1.8降至1.5±1.9(P=.024)。
  • 病例组4小时胃排空滞留率从45%±25.8%改善至16.6%±13.1%(P=.06)。
  • 恶心/呕吐子量表平均改善幅度病例组1.3±.6 vs 对照组.9±1.1(P=.044),病例组高于对照组。
  • 腹胀子量表平均改善幅度病例组1.6±1.3 vs 对照组1.2±1.4(P=.041),病例组高于对照组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Gastric neurostimulation (GNS) and gastric peroral myotomy (G-POEM), therapies for refractory gastroparesis, are associated with suboptimal outcomes. We studied the role of G-POEM as a salvage therapy in patients with refractory symptoms after GNS implantation. METHODS: This was a multicenter, retrospective, matched case-control study. Consecutive patients with a GNS device and who underwent G-POEM as a salvage therapy for clinical failure (cases) and patients without GNS implantation and who underwent G-POEM for refractory gastroparesis (control) between October 2018 and August 2021 were included. The primary outcome was clinical success after G-POEM. RESULTS: A total of 123 patients (mean age 45.7 ± 14.7 years; 88 female subjects [72%]) underwent G-POEM therapy during the study: 41 cases and 82 controls. Clinical success was achieved in 66% in the case group and 65% in the control group (P = .311), during a median total clinical follow-up time of 11.8 (interquartile range, 2.4-6.3) months. In the case group, the mean Gastroparesis Cardinal Symptom Index score decreased from 2.8 ± 1.8 to 1.5 ± 1.9 (P = .024), and gastric retention at 4 hours improved from 45% ± 25.8% to 16.6% ± 13.1% (P = .06). The mean delta improvement in the subscales of nausea/vomiting (1.3 ± .6 vs .9 ± 1.1, P = .044) and bloating (1.6 ± 1.3 vs 1.2 ± 1.4, P = .041) were significantly higher in cases than in controls. CONCLUSIONS: Among patients with refractory symptoms after GNS, G-POEM can be a reasonable salvage therapy to provide further symptomatic relief with evidence of a potential additive effect of both G-POEM and GNS.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Ichkhanian Y, Al-Haddad MA, Jacobs CC, et al. Gastric peroral endoscopic myotomy for management of refractory gastroparesis in patients with gastric neurostimulator devices: a multicenter retrospective case control study. Gastrointest Endosc. 2023. PMID: 37121364. doi:10.1016/j.gie.2023.04.2079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。